|
|
Limited time offer ~ all products 25% off
|
|
|
|
|
Stage I Diagnostics, Inc. (Stage I) is a Delaware C-Corp founded in 2005 to commercialize a panel of novel diagnostic tests capable of detecting early stage ovarian cancer as well as other reproductive tract cancers such as prostrate cancer.
Early detection of ovarian cancer, which primarily affects postmenopausal women, could save up to 50,000 lives a year. Complimentary markers to CA125 are clearly needed to effectively monitor all ovarian cancer patients and to provide a panel of markers to diagnose early stage disease.
To date, Stage I has produced serum based diagnostic tests for 5 new markers. These five markers, coupled with CA-125, comprise an initial diagnostic panel that has been verified for efficacy utilizing a limited set of serum samples. The complimentary tests include MMP-7, SCCE (KLK7), TADG-14 (KLK8), TADG-15 (Matriptase), and ALP (SLPI) for which Stage I holds composition of matter patents and/or use patents for cancer diagnosis.
Reagents, antibodies, and antigens for these assays are available individually and in kit form.
Products:
Antibodies
Kits
Antigen |
|
|
|
|
|
|
|
|
|
